Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingscheid, Tilman, Kinzig, Martina, Krüger, Anne, Müller, Nils, Bölke, Georg, Tober-Lau, Pinkus, Münn, Friederike, Kriedemann, Helene, Witzenrath, Martin, Sander, Leif E., Sörgel, Fritz, Kurth, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664846/
https://www.ncbi.nlm.nih.gov/pubmed/36286542
http://dx.doi.org/10.1128/aac.01229-22
_version_ 1784831184735305728
author Lingscheid, Tilman
Kinzig, Martina
Krüger, Anne
Müller, Nils
Bölke, Georg
Tober-Lau, Pinkus
Münn, Friederike
Kriedemann, Helene
Witzenrath, Martin
Sander, Leif E.
Sörgel, Fritz
Kurth, Florian
author_facet Lingscheid, Tilman
Kinzig, Martina
Krüger, Anne
Müller, Nils
Bölke, Georg
Tober-Lau, Pinkus
Münn, Friederike
Kriedemann, Helene
Witzenrath, Martin
Sander, Leif E.
Sörgel, Fritz
Kurth, Florian
author_sort Lingscheid, Tilman
collection PubMed
description Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.
format Online
Article
Text
id pubmed-9664846
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-96648462022-11-15 Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis Lingscheid, Tilman Kinzig, Martina Krüger, Anne Müller, Nils Bölke, Georg Tober-Lau, Pinkus Münn, Friederike Kriedemann, Helene Witzenrath, Martin Sander, Leif E. Sörgel, Fritz Kurth, Florian Antimicrob Agents Chemother Antiviral Agents Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment. American Society for Microbiology 2022-10-26 /pmc/articles/PMC9664846/ /pubmed/36286542 http://dx.doi.org/10.1128/aac.01229-22 Text en Copyright © 2022 Lingscheid et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Lingscheid, Tilman
Kinzig, Martina
Krüger, Anne
Müller, Nils
Bölke, Georg
Tober-Lau, Pinkus
Münn, Friederike
Kriedemann, Helene
Witzenrath, Martin
Sander, Leif E.
Sörgel, Fritz
Kurth, Florian
Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title_full Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title_fullStr Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title_full_unstemmed Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title_short Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
title_sort pharmacokinetics of nirmatrelvir and ritonavir in covid-19 patients with end-stage renal disease on intermittent hemodialysis
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664846/
https://www.ncbi.nlm.nih.gov/pubmed/36286542
http://dx.doi.org/10.1128/aac.01229-22
work_keys_str_mv AT lingscheidtilman pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT kinzigmartina pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT krugeranne pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT mullernils pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT bolkegeorg pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT toberlaupinkus pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT munnfriederike pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT kriedemannhelene pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT witzenrathmartin pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT sanderleife pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT sorgelfritz pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis
AT kurthflorian pharmacokineticsofnirmatrelvirandritonavirincovid19patientswithendstagerenaldiseaseonintermittenthemodialysis

Ejemplares similares